Rheumatology
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
Conference Coverage
Inadequate pain relief in OA, high opioid use before TKA
Rates of inadequate pain relief in knee and hip OA, and high opioid use before total knee replacement surgery were reported in separate studies at...
Conference Coverage
Weight gain may exacerbate structural damage in knee OA
Weight changes can have a significant effect on the structural progression of knee OA, according to new findings from Osteoarthritis Initiative...
Conference Coverage
Medical cannabis may cut opioid use for back pain, OA
Preliminary data suggest more than one-third of people with back pain no longer used opioids after filling cannabis prescriptions. Opioid...
Conference Coverage
COVID-19 infection linked to risk of cutaneous autoimmune and vascular diseases
“Our theory is that the severe inflammatory nature of COVID-19 leads to a lot of internal organ damage and exposure of autoantigens in that...
News
New MIS-C guidance addresses diagnostic challenges, cardiac care
New updates in this third version of the American College of Rheumatology’s guidance include a recommendation for dual therapy with IVIg and...
News
New ivermectin, HCQ scripts highest in GOP-dominated counties
Rates of new hydroxychloroquine (HCQ) prescriptions particularly increased in highly Republican counties after the Food and Drug Administration...
News
Updated guidance for COVID vaccination in rheumatology patients arrives amid continued hesitancy
A fifth update to the American College of Rheumatology’s guidelines makes new recommendations on supplemental and booster doses in patients with...
News
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.
News
Allopurinol found safe in patients with concomitant gout, CKD
Despite earlier concerns, a study has found no sign of increased mortality with allopurinol therapy in patients with gout and chronic kidney...